Oncocyte corp (OCX)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
CASH FLOWS FROM OPERATING ACTIVITIES:
NET LOSS

-7,732

-7,954

-5,225

-5,383

-3,864

-4,499

-2,971

-4,506

-3,778

-3,960

-6,906

-3,805

-4,704

-3,103

-2,594

-2,543

-2,928

-3,539

-2,416

-1,411

-1,369

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense

60

66

84

84

110

121

110

104

103

101

93

77

67

43

48

44

10

9

11

10

11

Amortization of intangible assets

15

-

-

-

-

0

0

60

61

61

60

60

61

61

60

60

61

61

60

60

61

Amortization of right-of-use assets and liabilities

152

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Pro rata loss from equity method investment in Razor

-329

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of prepaid maintenance

36

9

10

9

9

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation

937

786

821

702

686

400

344

388

347

-

-

-

-

-

-

-

-

-

-

-

216

Stock-based compensation

-

-

-

-

-

-

-

-

-

-

462

346

350

303

258

236

125

-

-

-

-

Loss on sale of BioTime shares

-

-

-

-

-

-

-

-

-

0

0

-150

-159

-

-

-

-

-

-

-

-

Unrealized gain (loss) on marketable equity securities

-53

-36

-103

-88

178

-498

103

-222

190

-

0

0

0

-

-

-

-

-

-

-

-

Warrants issued to certain shareholders as inducement to exercise of warrants

-

-

-

-

-

-

-

-

-

0

2,990

0

1,084

-

-

-

-

-

-

-

-

Loss on sale of BioTime shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Warrants issued to certain shareholders as inducement of exercise of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

Amortization of debt issuance costs

35

29

8

10

12

15

18

22

22

26

27

27

3

-

0

0

0

-

-

-

-

Deferred income tax benefit

-1,095

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other

-

82

-1

0

26

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

-8

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amount due to Lineage and affiliates

-6

6

-4

5

-2,101

-10

11

-6

7

-3

-437

-69

-244

597

418

368

624

267

-83

326

1,047

Amount due to affiliates

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

31

-181

31

Prepaid expenses and other assets

909

-36

-302

-410

950

-66

-137

-110

324

-234

-75

28

166

96

62

-133

-126

368

-27

-36

-31

Accounts payable and accrued liabilities

1,247

1,157

-1,183

1,235

-468

1,041

-40

-998

999

-275

166

-39

100

-319

838

-105

-185

767

291

176

-192

Net cash used in operating activities

-6,870

-5,306

-4,851

-2,840

-6,718

-2,456

-2,483

-3,957

-2,753

-3,344

-3,470

-3,281

-3,290

-

-

-

-

-

-

-

-

CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of Insight Genetics, net of cash acquired

6,189

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,167

-

-1,386

-984

-164

Net proceeds from sale of BioTime shares

-

-

-

-

-

-

-

-

-

0

0

432

502

0

0

0

0

-

-

-

-

Purchase of equipment

44

900

0

11

7

0

9

17

5

6

30

39

16

87

9

-5

15

489

0

0

11

Security deposit and other

-42

316

-10

0

-54

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

-6,191

-1,216

-11,235

-11

47

0

-9

-17

-5

-6

-30

393

486

-

-

-

-

-

-

-

-

CASH FLOWS FROM FINANCING ACTIVITIES:
Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-15

-

44

0

-11

Proceeds from exercise of stock options

-

0

0

0

943

0

2

5

51

145

208

241

16

135

1

40

42

0

4

0

0

Proceeds from exercise of warrants

-

-

-

-

-

-

-

-

-

0

5,743

0

2,031

0

0

0

0

-

-

-

-

Proceeds from sale of common shares

7,597

8,600

0

0

40,250

0

0

2,000

8,000

-

0

0

0

-

-

-

-

-

-

-

-

Financing costs to issue common shares

1

36

0

287

2,965

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Common shares received and retired for employee taxes paid

14

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of loan payable, net of financing costs

-

-

-

-

-

-

-

-

-

0

0

0

1,982

0

0

0

0

-

-

-

-

Repayment of loan payable

-

67

200

200

200

200

200

200

200

133

0

0

0

-

-

-

-

-

-

-

-

Repayment of financing lease obligations

17

131

96

93

134

131

85

84

81

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of capital lease obligation

-

-

-

-

-

-

-

-

-

86

71

61

47

40

34

40

0

-

-

-

-

Net cash provided by financing activities

7,565

10,850

-296

-580

37,894

-331

3,019

1,656

7,770

-74

5,880

180

3,982

-

-

-

-

-

-

-

-

NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

-5,496

4,328

-16,382

-3,431

31,223

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

CASH, CASH EQUIVALENTS AND RESTRICTED CASH:
Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

42

-

8,354

3,300

0

NET INCREASE IN CASH AND CASH EQUIVALENTS

-

-

-

-

-

-

-

-

5,012

-3,424

2,380

-2,708

1,178

-2,500

8,674

-1,856

-2,140

-1,414

7,012

2,316

-175

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest

43

-

-

-

30

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES
Common stock issued for acquisition of Insight Genetics

5,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Initial fair value of contingent consideration at acquisition date

11,130

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Holdback liability

600

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred final commitment fee for bank loan

35

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-